Ritholtz Wealth Management Acquires Shares of 24,319 Takeda Pharmaceutical Company Limited (NYSE:TAK)

Ritholtz Wealth Management bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 24,319 shares of the company’s stock, valued at approximately $315,000.

Several other hedge funds also recently made changes to their positions in TAK. Apollon Wealth Management LLC bought a new position in Takeda Pharmaceutical during the 4th quarter worth $219,000. Principal Securities Inc. bought a new position in shares of Takeda Pharmaceutical in the fourth quarter worth $28,000. NBC Securities Inc. raised its stake in Takeda Pharmaceutical by 3.5% in the fourth quarter. NBC Securities Inc. now owns 42,774 shares of the company’s stock valued at $610,000 after purchasing an additional 1,440 shares in the last quarter. Formidable Asset Management LLC bought a new stake in Takeda Pharmaceutical during the fourth quarter worth about $195,000. Finally, Envestnet Portfolio Solutions Inc. grew its stake in Takeda Pharmaceutical by 7.3% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 23,985 shares of the company’s stock worth $342,000 after buying an additional 1,626 shares in the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $14.92 on Friday. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $16.39. The firm has a market capitalization of $47.22 billion, a price-to-earnings ratio of 27.13, a P/E/G ratio of 0.27 and a beta of 0.54. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The firm’s 50 day simple moving average is $13.96 and its 200 day simple moving average is $13.75.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. The firm had revenue of $7.75 billion for the quarter. As a group, research analysts expect that Takeda Pharmaceutical Company Limited will post 1.63 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.